Friday, 19 Jul 2019

You are here

Omega-3 Rich Fish Lowers Gout Flares

Boston researchers have shown that consumption of fish rich in omega‐3 polyunsaturated fatty acids (n‐3 PUFA) leads to a lower risk of recurrent gout flares.

They used a novel internet‐based, case‐crossover study conducted from 2003‐2012 (the Boston University Online Gout Study). They questioned gout patients about gout flares, and during gout flare‐free periods their intake of n‐3 PUFA‐rich supplements and fish intake, total purine intake, diuretic use, and other arthritis and urate‐lowering medications (allopurinol, non‐steroidal anti‐inflammatory drugs, colchicine).

Of the 724 participants, 85% met the 1977 Preliminary ACR classification criteria for acute gout.

In all patients (flare and non-flare; n=724 patients), 22% reported ingesting form of n‐3 PUFA consumption (supplements: 4.6%; dietary fatty fish: 19%) in the prior 48 hours. 

While any ingestion of n-3 PUFA did not affect gout flares (aOR 1.01; 95% CI, 0.63‐1.60; p=0.98), those who had two or more servings of n‐3 PUFA‐rich fish had a lower risk of gout flares (aOR 0.74; 95% CI, 0.54‐0.99; p=0.04).

Supplement use with either Omega 3, cod liver oil or fish oil supplements did not lower the risk of recurrent gout flares.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Excess Non-CV Mortality Persists in Gout

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.